BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with complement-mediated and other rare diseases [3] - The company specializes in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases [3] - BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [3] Stock Options and RSUs Grant - BioCryst's board of directors granted stock options to nine newly-hired employees, allowing them to purchase a total of 32,100 shares, along with restricted stock units (RSUs) covering 21,450 shares [1] - The options have an exercise price of $5.30 per share, equal to the closing price of BioCryst common stock on the grant date [2] - The options and RSUs will vest in four equal annual installments starting on the one-year anniversary of the grant date, contingent on the employees' continued service with the company [2]